Ich stimme der Verwendung von Cookies zu. Auch wenn ich diese Website weiter nutze, gilt dies als Zustimmung.

Bitte lesen und akzeptieren Sie die Datenschutzinformation und Cookie-Informationen, damit Sie unser Angebot weiter nutzen können. Natürlich können Sie diese Einwilligung jederzeit widerrufen.






21st Austria weekly - Immofinanz, Marinomed (21/11/2022)

27.11.2022

Immofinanz: Austrian based real estate company Immofinanz enters into negotiations with its core shareholder CPI Property Group concerning the acquisition of shares in S Immo. Currently, Immofinanz directly holds approx. 26.49% of S Immo. CPI Property Group directly holds 52.7% of S Immo, which may further increase as a result of CPI Property Group’s mandatory takeover offer over S Immo. A potential acquisition of shares in S Immo by Immofinanz from CPI Property Group would be envisaged to take place by the end of 2022. The potential transaction would involve at least 17,305,012 shares in S Immo (approx. 23.51%). For the purchase price, a long-term financing by CPI Property Group to Immofinanz should take place. With this acquisition, Immofinanz would complete a long-term strategic goal and proceed with the consolidation of both companies to capture future mutual synergies.

Marinomed: Marinomed Biotech, an Austrian science-based biotech company with globally marketed therapeutics, reported today strong financial results for the first nine months of the financial year 2022. Revenues for the first 9 months of 2022 increased to Euro 7.1 mn compared to the previous year (9M 2021 Euro 5.7m; +24%). Out of Marinomed’s three business segments - virology, immunology, and other, which includes Solv4U - the virology segment recorded the largest portion of revenues with sustained high sales of the virus blocker Carragelose. The operating result (EBIT) amounted to Euro -3.8 mn, which marks an improvement over the same period in 2021 (9M 2021: Euro -5.2 mn). Net loss for that period was Euro 5.8 m compared to Euro 6.3 m in in the first nine months of 2021. The Company expects Carragelose revenues in the double digit million range, but an operating loss for 2022. Given the promising progress in its partnerships, Marinomed plans to reach operating profitability in the medium term.

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (21/11/2022)


Partners









latest 21st Austria

21st Austria weekly - Immofinanz, Marinomed (21/11/2022)


27.11.2022, 1977 Zeichen



Immofinanz: Austrian based real estate company Immofinanz enters into negotiations with its core shareholder CPI Property Group concerning the acquisition of shares in S Immo. Currently, Immofinanz directly holds approx. 26.49% of S Immo. CPI Property Group directly holds 52.7% of S Immo, which may further increase as a result of CPI Property Group’s mandatory takeover offer over S Immo. A potential acquisition of shares in S Immo by Immofinanz from CPI Property Group would be envisaged to take place by the end of 2022. The potential transaction would involve at least 17,305,012 shares in S Immo (approx. 23.51%). For the purchase price, a long-term financing by CPI Property Group to Immofinanz should take place. With this acquisition, Immofinanz would complete a long-term strategic goal and proceed with the consolidation of both companies to capture future mutual synergies.

Marinomed: Marinomed Biotech, an Austrian science-based biotech company with globally marketed therapeutics, reported today strong financial results for the first nine months of the financial year 2022. Revenues for the first 9 months of 2022 increased to Euro 7.1 mn compared to the previous year (9M 2021 Euro 5.7m; +24%). Out of Marinomed’s three business segments - virology, immunology, and other, which includes Solv4U - the virology segment recorded the largest portion of revenues with sustained high sales of the virus blocker Carragelose. The operating result (EBIT) amounted to Euro -3.8 mn, which marks an improvement over the same period in 2021 (9M 2021: Euro -5.2 mn). Net loss for that period was Euro 5.8 m compared to Euro 6.3 m in in the first nine months of 2021. The Company expects Carragelose revenues in the double digit million range, but an operating loss for 2022. Given the promising progress in its partnerships, Marinomed plans to reach operating profitability in the medium term.

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (21/11/2022)



BSN Podcasts
Christian Drastil: Wiener Börse Plausch

Börsenradio Live-Blick, Fr. 19.4.24: DAX eröffnet zum April-Verfall deutlich schwächer, Beiersdorf und adidas stark, Gold auch




 

Bildnachweis

Aktien auf dem Radar:Amag, Palfinger, SBO, Addiko Bank, Flughafen Wien, Austriacard Holdings AG, EVN, EuroTeleSites AG, Pierer Mobility, Semperit, Bawag, Kostad, Wolford, Oberbank AG Stamm, Polytec Group, ams-Osram, Agrana, CA Immo, Erste Group, Immofinanz, Kapsch TrafficCom, Mayr-Melnhof, OMV, Österreichische Post, Strabag, Telekom Austria, Uniqa, VIG, Wienerberger, Covestro, Sartorius.


Random Partner

Wolftank-Adisa
Die Wolftank-Adisa Holding AG ist die Muttergesellschaft einer internationalen Unternehmensgruppe mit Fokus auf Sanierung und Überwachungen von (Groß–)Tankanlagen und Umweltschutz-Dienstleistungen bei verseuchten Böden und Einrichtungen.

>> Besuchen Sie 68 weitere Partner auf boerse-social.com/partner


Useletter

Die Useletter "Morning Xpresso" und "Evening Xtrakt" heben sich deutlich von den gängigen Newslettern ab. Beispiele ansehen bzw. kostenfrei anmelden. Wichtige Börse-Infos garantiert.

Newsletter abonnieren

Runplugged

Infos über neue Financial Literacy Audio Files für die Runplugged App
(kostenfrei downloaden über http://runplugged.com/spreadit)

per Newsletter erhalten